ICD market rebound?
This article was originally published in The Gray Sheet
Executive Summary
Further confirming that the recently plagued implantable cardioverter defibrillator market has at least stabilized and could return to healthy single-digit growth in 2007, St. Jude Medical reports a 15% year-over-year advance in its ICD revenue for the first quarter, to $302 million. The gain includes 10% U.S. ICD growth and 31% expansion overseas. During the firm's April 19 earnings call, it reiterated a projection that the overall market will grow 3% to 9% this year (1"The Gray Sheet" Feb. 19, 2007, p. 15). St. Jude's Q1 ICD sales growth stemmed in part from market share gains, according to the company. Competitors include Medtronic and Boston Scientific; the latter firm will report Q1 results April 23. St. Jude reported total corporate sales of $887 million for the quarter, an increase of 13% over the prior-year period. Separately, the firm announced April 18 FDA go-ahead for its Merlin.net patient care network, an internet-based central repository for data on patients' implantable cardiac devices accessible to physicians. Merlin.net collects data from in-clinic follow-up sessions and remote data transmissions from patients using the currently available Housecall Plus portable transmitter...
You may also be interested in...
Analysts And Doctors Predict Continued Malaise In U.S. ICD Market
The U.S. implantable defibrillator market will remain stagnant for the foreseeable future, while overseas demand for the devices will stay strong, according to a report from Morgan Stanley's device industry analysts
St. Jude Expects ICD Investments To Bear Fruit In 2007
St. Jude Medical predicts that investments it made last year in its implantable cardioverter defibrillator business will allow it to capture market share as the ICD market rebounds in 2007
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”